847798-79-2

Upstream product

• 10389-51-2 1-morpholino-4-nitrobenzene 
• 755039-80-6 trans-dibenzyl-(4-morpholin-4-yl-cyclohexyl)-amine 
• 110-91-8 morpholine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 558442-96-9 tert-butyl N-[4-(morpholin-4-yl)cyclohexyl]carbamate 
• 177906-48-8 trans-N-Boc-1,4-cyclohexanediamine 
• 1246532-37-5 tert-Butyl trans-4-(4-morpholinyl)cyclohexylcarbamate 
• 100-00-5 4-chlorobenzonitrile 

Relevant academic research and scientific papers

TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS

This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.

PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and Rs

2, 4-DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention encompasses compounds of general formula (1) wherein Q and R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the

New pyridodihydropyrazinones, process for their manufacture and use thereof as medicaments

Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, Rsup

2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS

The invention relates to compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1, and R3 are defined as indicated in claim 1. Said compounds are used for the treatment of diseases characterized by excessive or anomalous cell proliferation. Also disclosed is the use of the inventive compounds for producing a medicament having said properties.

PI3 KINASES

The invention relates to the novel compounds of formula (1), which, due to their pharmaceutical effect as PI3 kinase modulators, are suitable for use in the therapy and treatment of inflammatory or allergic diseases. Examples of these diseases are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastro-intestinal system and of the locomotor apparatus, inflammatory and allergic skin diseases, inflammatory ophthalmic diseases, diseases of the nasal mucosa, inflammatory or allergic autoimmune reactive conditions, or renal inflammations.

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.